DISCLAIMERThe information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.
Trusted Resources: News & Events
Latest announcements and gatherings
Memantine, a standard treatment for Alzheimer’s disease, has shown promise in treating sickle cell disease (SCD) in six patients, a 12-month pilot clinical trial found. The findings were presented at the American Physiological Society’s Physiological and Pathophysiological Consequences of Sickle Cell Disease conference in Washington, D.C.
The study’s lead researcher, Anna Bogdanova PhD, presented the paper, titled “Treatment of the First Sickle Cell Disease Patients with Antagonist of N-Methyl D-Aspartate Receptor Memantine: Biological Outcome of the MemSID Trial.” Calcium levels in the red blood cells (RBCs) of people with SCD are often excessive. The team of Swiss researchers reasoned that inhibiting a kind of receptor on the cells, known as an NMDA receptor, which when activated allows calcium to enter cells, might reduce the damage potentially caused by calcium in the red blood cells of SCD patients.
videos & visualsFacebook Live: Stem Cells and Sickle Cell Diseasehttps://www.youtube.com/watch?v=IPzNx8i_...
education & research8 Tips to Support Students With Sickle Cell DiseaseIn the United States, sickle cell diseas...
education & researchImproving vaso-occlusive crisis (VOC) management for those living with sickle cell diseaseThe Sickle Cell Disease Council For CHAN...
news & eventsbluebird bio Announces Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene ...Patient treated with LentiGlobinTM drug ...
news & eventsMaxCyte and U.S. National Institutes of Health’s National Heart, Lung, and Blood Institute enter cooperative r...MaxCyte, Inc. today announces it has e...
news & eventsNIH Launches new Collaboration to Develop Gene-Based Cures for Sickle Cell Disease and HIV on Global ScaleThe National Institutes of Health plans ...
Community Center3 Gene Editing Approaches for Sickle Cell DiseaseSickle cell disease (SCD) is a perfect c...
send a message
Don’t forget to join the oneSCDvoice community!
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.